LCN2 has been proposed as a biomarker for preclinical Alzheimer’s disease and vascular dementia (53, 54); its usage as a potential biomarker for PD still needs to be further explored. Here, LCN2 is linked to early-onset autosomal dominant Alzheimer disease.